Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Researchers at the Perelman School of Medicine at the University of Pennsylvania have discovered a novel type of cell buried in healthy human lung tissue.
Speakers at the 2022 Virtual Growth Conference’s session on pancreatic cancer acknowledged the exceptional challenges while extolling advances in immune-based therapies and combination approaches.
Requesting disability accommodations is vital for your success in the workplace. You can find out everything about how to ask for accommodations in our guide.
BMS partnered with digital oncology company GRYT Health to convene a series of “courageous conversations” between patients, practitioners, caregivers, clinical trial teams and public health leaders.
Celeris Therapeutics and Boehringer Ingelheim (BI) have announced they are entering into a collaboration to develop next-generation targeted protein degraders.
This morning, Merck hosted a cardiovascular investment event where it touted the advances it’s made in its pipeline, which includes a portfolio that has tripled in size over the past year.
Biolojic Design announced that the first-ever computationally-designed human antibody will enter the clinic. The company will study AU-007 in solid cancer tumors.
Moderna’s CEO Stéphane Bancel spoke at the Boston College Chief Executives Club on Monday and recapped the laundry list of vaccines and treatments the company plans to develop.
Discover what’s in store for today’s presentations at The American Academy of Neurology’s annual meeting, which will include data for a variety of neurological treatments.
Imara stock plunged 40% after announcing the failure of Phase II sickle cell and beta-thalassemia trials and plans to discontinue development.
Stephane Bancel, the chief executive of Moderna, has likened the need for booster vaccine doses to the way Apple releases new smartphones every year.
With the close of these two funds, Andrew Schwab, managing partner at 5AM Ventures, said the firm has raised more than $2.2 billion to invest in the life sciences industry.
PRESS RELEASES
Head-to-Head Study Highlights Rocbrutinib as the World’s First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations
Corporate Treasury Positioned with Cash and Liquid Equity Holdings to Seed, Incubate and Accelerate New and Existing Operations